Organon and Radboud University Nijmegen Medical Centre announce new research collaboration

20-Apr-2006

NV Organon and Radboud University Nijmegen Medical Centre announced that they have entered into a new research collaboration. The two-year collaboration and license agreement will endeavor to prove the principle for the therapeutic efficacy of targeting an undisclosed gene in the oncology field identified by scientists at the Medical Centre.

The collaboration will leverage Organon's proprietary monoclonal antibody technology and the Medical Centre's expertise in oncology to investigate whether the target - that is indicated to be involved in tumor growth - may form the basis of a novel cancer treatment.

"This exciting research collaboration reflects Organon's determination to strengthen its existing biotechnology expertise and expand our activities into the oncology field," said David Nicholson, Executive Vice President Research and Development, Organon International, "The early work will be undertaken by scientists at our Organon Research Center USA in Cambridge, Massachusetts recently established to expand the breadth and depth of our biotechnology research program."

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances